A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
Public ClinicalTrials.gov record NCT07333183. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Phase 2 Study Evaluating the Safety of Mosliciguat in Combination With Inhaled Treprostinil in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.
Study identification
- NCT ID
- NCT07333183
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 23, 2025 (Actual)
- Primary completion
- Dec 2026 (Estimated)
- Completion
- Jan 2028 (Estimated)
- Last update posted
- Sep 2, 2026
2025 – 2028
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research Site | Santa Barbara | California | 93105 | Recruiting |
| Clinical Research Site | Torrance | California | 90502 | Recruiting |
| Clinical Research Site | Kissimmee | Florida | 34746 | Recruiting |
| Clinical Research Site | Chicago | Illinois | 60611 | Recruiting |
| Clinical Research Site | Kansas City | Kansas | 66160 | Recruiting |
| Clinical Research Site | Boston | Massachusetts | 02115 | Recruiting |
| Clinical Research Site | Ann Arbor | Michigan | 48109 | Recruiting |
| Clinical Research Site | Detroit | Michigan | 48202 | Recruiting |
| Clinical Research Site | Albuquerque | New Mexico | 87131 | Recruiting |
| Clinical Research Site | Greensboro | North Carolina | 27403 | Recruiting |
| Clinical Research Site | Providence | Rhode Island | 02903 | Recruiting |
| Clinical Research Site | Charleston | South Carolina | 29425 | Recruiting |
| Clinical Research Site | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07333183, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07333183 live on ClinicalTrials.gov.